Taiwan's Mycenax and Sartorius have entered into a strategic partnership to create comprehensive biopharmaceutical manufacturing solutions. This collaboration will combine both companies' core strengths, enhance service capabilities, and expand their global market impact, with more efficient, flexible, and complete CDMO services.
Mycenax is a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that has successfully completed more than 150 protein drug process development and GMP projects. Mycenax is renowned for its highly flexible technical services, specializing in tailoring customized process solutions based on the unique characteristics of different protein drugs.
Seven new drugs and biosimilars have been successfully launched using Sartorius' CHO cell line platform, which provides each drug with a high-quality, high-performance cell line as a production foundation at an early stage of development.
The alliance will enable Mycenax to expand its service offering beyond its existing high efficiency cell line platform to include Sartorius's CHO cells, completing subsequent process development and GMP production internationally. From raw materials to large-scale manufacturing and sterile filling, this will facilitate the rapid advancement of protein drugs into clinical trials.
